Anirban Maitra, Scientific Director of Sheikh Ahmed Center for Pancreatic Cancer Research and Professor of Pathology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center, shared a post on X about a recent article by Valerie S. Kalluri et al, adding:
“Are Hedgehog inhibitors making a comeback in Pancreatic Cancer, this time with nuanced sequencing and combination regimen? Preprint of 1st line clinical trial in advanced PDAC, Manuel Hidalgo,(in collaboration with Valerie S. Kalluri, Raghu Kalluri).
The sequencing of Hh inhibitor, chemotherapy and immune checkpoint inhibitor is KEY here, and a great example of how biology gleaned from preclinical models informed the clinical regimen. 1st you ‘prime’, then you come all-in with the ‘attack'”.
Title: Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trial
Authors: Valerie S. Kalluri, Bruno Bockorny, Evelio Perea Borobio, Teresa Macarulla, Roberto Pazo Cid, Laura Medina, Aitziber Gil-Negrete, Fernando Rivera, Vanesa Varela, Alejandro Martin-Munoz, Yanira Ruiz-Heredia, Bingrui Li, Patience Kelly, Barbara Moreno Diaz, Shreyasee V Kumbar, Hikaru Sugimoto, Raghu Kalluri, Manuel Hidalgo
Read the Full Article on medRxiv
More posts featuring Anirban Maitra.
